% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Walle:180369,
      author       = {T. Walle$^*$ and S. Bajaj$^*$ and J. A. Kraske$^*$ and T.
                      Rösner and C. S. Cussigh and K. A. Kälber and L. J.
                      Müller and S. B. Strobel and J. Burghaus and S. M.
                      Kallenberger and C. Stein-Thöringer$^*$ and M. Jenzer and
                      A. Schubert$^*$ and S. Kahle and A. Williams and B.
                      Hoyler$^*$ and L. Zielske and R. Skatula and S. Sawall$^*$
                      and M. F. Leber$^*$ and R. Z. Kunes and J. Krisam and C.
                      Fremd and A. Schneeweiss and J. Krauss and L. Apostolidis
                      and A. K. Berger and G. M. Haag$^*$ and S. Zschäbitz and N.
                      Halama$^*$ and C. Springfeld and R. Kirsten and J.
                      Hassel$^*$ and D. Jäger$^*$ and G. Ungerechts$^*$ and C. S.
                      Cussigh and K. A. Kälber and O. Abdelrahim and E. Busch and
                      P. Derigs and K. Dischinger and F. Mitri and K. Schmidt and
                      I. A. Bhatti and B. Grün and N. Hohmann and L. Woydack and
                      X.-W. Zhang and D. Ferber and A. Mock and T. Pompecki and T.
                      Schank and C. Fremd and G. M. Haag and N. Halama and R.
                      Kirsten and J. C. Hassel and D. Jäger$^*$ and G.
                      Ungerechts$^*$},
      collaboration = {N. A. Investigators},
      title        = {{C}ytokine release syndrome-like serum responses after
                      {COVID}-19 vaccination are frequent and clinically
                      inapparent under cancer immunotherapy.},
      journal      = {Nature cancer},
      volume       = {3},
      number       = {9},
      issn         = {2662-1347},
      address      = {London},
      publisher    = {Nature Research},
      reportid     = {DKFZ-2022-01283},
      pages        = {1039-1051},
      year         = {2022},
      note         = {#EA:F230#F230# / 2022 Sep;3(9):1039-1051 / HI-TRON},
      abstract     = {Patients with cancer frequently receive immune-checkpoint
                      inhibitors (ICIs), which may modulate immune responses to
                      COVID-19 vaccines. Recently, cytokine release syndrome (CRS)
                      was observed in a patient with cancer who received BTN162b2
                      vaccination under ICI treatment. Here, we analyzed adverse
                      events and serum cytokines in patients with 23 different
                      tumors undergoing (n = 64) or not undergoing (n = 26)
                      COVID-19 vaccination under ICI therapy in a prospectively
                      planned German single-center cohort study (n = 220). We did
                      not observe clinically relevant CRS (≥grade 2) after
                      vaccination $(95\%$ CI $0-5.6\%;$ Common Terminology of
                      Adverse Events v.5.0) in this small cohort. Within 4 weeks
                      after vaccination, serious adverse events occurred in eight
                      patients $(12.5\%$ $95\%$ CI $5.6-23\%),$ six patients were
                      hospitalized and two patients died. Despite absence of CRS
                      symptoms, a set of pairwise-correlated CRS-associated
                      cytokines, including CXCL8 and interleukin-6 was >1.5-fold
                      upregulated in $40\%$ $(95\%$ CI $23.9-57.9\%)$ of patients
                      after vaccination. Hence, elevated cytokine levels are
                      common and not sufficient to establish CRS diagnosis.},
      cin          = {F230 / HD01 / E055 / F220 / B110 / D120 / D240},
      ddc          = {610},
      cid          = {I:(DE-He78)F230-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)E055-20160331 / I:(DE-He78)F220-20160331 /
                      I:(DE-He78)B110-20160331 / I:(DE-He78)D120-20160331 /
                      I:(DE-He78)D240-20160331},
      pnm          = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
      pid          = {G:(DE-HGF)POF4-316},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35715501},
      doi          = {10.1038/s43018-022-00398-7},
      url          = {https://inrepo02.dkfz.de/record/180369},
}